Gilead Sciences, Inc
F:GIS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Gilead Sciences, Inc
F:GIS
|
US |
|
Orion180 Insurance Group Inc.
NASDAQ:OIG
|
US |
Intrinsic Value
The intrinsic value of 
Gilead Sciences, Inc (GIS) under the Base Case is 110.01 EUR per share.
Compared with the current market price of 153.1 EUR, the stock appears
Overvalued by 28% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Gilead Sciences Does
Gilead Sciences is a biopharmaceutical company that develops and sells prescription medicines, especially in antiviral treatments. Its best-known products have been used to treat HIV, hepatitis B and C, and it also sells medicines for cancer and inflammatory diseases. The company focuses on discovering drugs, testing them in clinical trials, getting them approved, and then manufacturing and marketing them to patients who need long-term treatment.
- Headquarters
- United States of America US
- Employees
- 17 000
- IPO date
- Jan 22, 1992
Gilead Sciences has a wide economic moat
Patents keep rivals from copying important Gilead medicines such as Biktarvy, allowing the company to earn profits from treatments competitors cannot freely reproduce. The medical review needed to change a successful HIV treatment also helps protect its established patient base, particularly when drug resistance limits alternatives.
Read the full moat analysis
Revenue & Expenses Breakdown
Gilead Sciences, Inc
Earnings Waterfall
Gilead Sciences, Inc
The intrinsic value for Gilead Sciences, Inc (GIS) under the Base Case is 110.01 EUR.
Compared with the current market price of 153.1 EUR, the stock appears Overvalued by 28% .
